NKGen Biotech (NKGN) Competitors $0.48 +0.04 (+9.45%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends NKGN vs. VHAQ, ZIVO, ONCY, ANVS, SLS, RVPH, BYSI, MURA, IMRX, and GBIOShould you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Viveon Health Acquisition (VHAQ), ZIVO Bioscience (ZIVO), Oncolytics Biotech (ONCY), Annovis Bio (ANVS), SELLAS Life Sciences Group (SLS), Reviva Pharmaceuticals (RVPH), BeyondSpring (BYSI), Mural Oncology (MURA), Immuneering (IMRX), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. NKGen Biotech vs. Viveon Health Acquisition ZIVO Bioscience Oncolytics Biotech Annovis Bio SELLAS Life Sciences Group Reviva Pharmaceuticals BeyondSpring Mural Oncology Immuneering Generation Bio Viveon Health Acquisition (NYSE:VHAQ) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings. Does the media refer more to VHAQ or NKGN? In the previous week, Viveon Health Acquisition's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score. Company Overall Sentiment Viveon Health Acquisition Neutral NKGen Biotech Neutral Do insiders and institutionals hold more shares of VHAQ or NKGN? 22.1% of Viveon Health Acquisition shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 75.3% of Viveon Health Acquisition shares are held by company insiders. Comparatively, 74.7% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is VHAQ or NKGN more profitable? Company Net Margins Return on Equity Return on Assets Viveon Health AcquisitionN/A N/A N/A NKGen Biotech N/A N/A -479.36% Which has more volatility and risk, VHAQ or NKGN? Viveon Health Acquisition has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Which has better valuation & earnings, VHAQ or NKGN? Viveon Health Acquisition has higher earnings, but lower revenue than NKGen Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViveon Health AcquisitionN/AN/A-$610KN/AN/ANKGen Biotech$80K212.97-$82.94M-$5.08-0.09 Does the MarketBeat Community prefer VHAQ or NKGN? Viveon Health Acquisition and NKGen Biotech both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformViveon Health AcquisitionN/AN/ANKGen BiotechN/AN/A SummaryViveon Health Acquisition and NKGen Biotech tied by winning 3 of the 6 factors compared between the two stocks. Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKGN vs. The Competition Export to ExcelMetricNKGen BiotechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$17.04M$3.01B$5.39B$20.04BDividend YieldN/A1.89%5.37%3.61%P/E Ratio-0.0946.0188.8341.77Price / Sales212.97291.451,282.2617.54Price / CashN/A189.5236.6017.54Price / Book-0.184.004.965.86Net Income-$82.94M-$40.99M$117.89M$1.01B7 Day Performance2.29%3.23%2.75%3.59%1 Month Performance-24.72%0.60%3.63%6.09%1 Year Performance-81.68%-0.09%27.27%20.27% NKGen Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKGNNKGen BiotechN/A$0.48+9.5%N/A-83.3%$17.04M$80,000.00-0.09N/AVHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002ZIVOZIVO BioscienceN/A$18.35-3.9%N/A+178.3%$66.45M$15,850.00-3.7610ONCYOncolytics Biotech1.3705 of 5 stars$0.82-5.4%$4.00+386.4%-34.6%$65.81MN/A-3.0530ANVSAnnovis Bio2.2439 of 5 stars$4.75-2.9%$31.40+561.1%-57.1%$65.54MN/A-1.073SLSSELLAS Life Sciences Group0.1965 of 5 stars$0.93-2.5%N/A+101.3%$65.39M$1M-1.3510Gap UpRVPHReviva Pharmaceuticals3.802 of 5 stars$1.96+4.0%$11.25+475.4%-56.9%$65.38MN/A-1.765Analyst ForecastOptions VolumeGap UpBYSIBeyondSpringN/A$1.63-1.8%N/A+95.0%$63.62M$1.88M0.0080Positive NewsGap DownMURAMural Oncology3.3134 of 5 stars$3.73-4.1%$16.00+329.0%-4.3%$63.49MN/A-0.41119Positive NewsGap DownIMRXImmuneering3.6564 of 5 stars$2.02-2.4%$12.80+533.7%-65.8%$62.72M$320,000.00-1.0360Gap UpGBIOGeneration Bio4.1972 of 5 stars$0.94+1.0%$6.50+595.1%-45.2%$62.46M$18.58M-0.43150Positive NewsGap Up Related Companies and Tools Related Companies Viveon Health Acquisition Alternatives ZIVO Bioscience Alternatives Oncolytics Biotech Alternatives Annovis Bio Alternatives SELLAS Life Sciences Group Alternatives Reviva Pharmaceuticals Alternatives BeyondSpring Alternatives Mural Oncology Alternatives Immuneering Alternatives Generation Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NKGN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
